The American Herbal Products Association is urging members and stakeholders to contact lawmakers to oppose the mandatory product listing language that has been attached to a ‘must pass’ fee reauthorization bill.
Mandatory Product Listing can still be a good idea for industry, proponents maintain, even if the latest legislative iteration has failed to garner support from stakeholders.
Three trade organizations joined forces in opposing the FDA Safety and Landmark Advancement Act of 2022 (FDASLA), a fee authorization bill that includes provisions aimed at tightening dietary supplement regulations.
As the uncertainty around the regulatory status of NAC (N-acetyl cysteine) continues, it is important the industry doesn’t lose this for the precedent it sets for other potential ingredients, said CRN’s Steve Mister.
